Sanofi SA
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
82,878
Stocks News & Analysis
retirement
The top shares of Australia’s best performing super funds
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,365.70 | 24.70 | 0.30% |
CAC 40 | 7,593.87 | 38.00 | 0.50% |
DAX 40 | 22,496.98 | 71.15 | 0.32% |
Dow JONES (US) | 40,752.96 | 83.60 | 0.21% |
FTSE 100 | 8,496.80 | 1.95 | 0.02% |
HKSE | 22,119.41 | 111.30 | 0.51% |
NASDAQ | 17,710.74 | 264.40 | 1.52% |
Nikkei 225 | 36,452.30 | 406.92 | 1.13% |
NZX 50 Index | 12,207.87 | 59.27 | 0.49% |
S&P 500 | 5,604.14 | 35.08 | 0.63% |
S&P/ASX 200 | 8,145.60 | 19.40 | 0.24% |
SSE Composite Index | 3,279.03 | 7.62 | -0.23% |